Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.
|Videos|August 6, 2014
Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer
Author(s)David Gandara, MD
David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.
Advertisement
Clinical Pearls
David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcomingKRASmutations in lung cancer. Gandara presented on this topic at the
- KRASmutations tend to predict less response to chemotherapy or TKIs.
- It has been extremely difficult to develop drugs that directly inhibit KRAS.
- MEK inhibitors in combination with chemotherapy have shown downstream activity.
- SWOG 1408 will test this hypothesis with a MEK inhibitor (trametinib) in combination with chemotherapy (docetaxel) or an AKT inhibitor (GSK795).
Advertisement
Related to this article
Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
4
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
5